Key result
Anti-CCP antibodies in rheumatoid arthritis linked to ischemic heart disease and higher mortality.
Why the study?
Does the presence of anti-CCP antibodies predict the development of ischemic heart disease and mortality in patients with rheumatoid arthritis?
Cohort (n=937)
Does the presence of anti-CCP antibodies predict the development of ischemic heart disease and mortality in patients with rheumatoid arthritis?
Answers are grounded in this paper and cite their sources.
In patients with rheumatoid arthritis, the presence of anti-CCP antibodies is an independent risk factor for ischemic heart disease and increased mortality.
Rheumatoid arthritis (RA) is a systemic autoimmune disease that causes chronic inflammation of the joints and several extra-articular manifestations that account for increased morbimortality of these patients. The involvement of B cells in RA pathophysiology was recognized early, with the discovery of rheumatoid factor antibody. Recently, a number of autoantibodies against citrullinated proteins have been described, of which anti-cyclic citrullinated peptide (anti-CCP) is the most specific for RA. A cohort of 937 patients with RA was studied to determine the clinical correlates of anti-CCP antibodies. The presence of anti-CCP antibodies correlated with worse joint involvement and several extra-articular manifestations, i.e., higher incidence of ischemic heart disease independent of classic cardiovascular factors and higher mortality rate. A multivariate logistic regression model showed that only anti-CCP antibodies were independently associated with the development of ischemic heart disease in patients with RA. The clinical value of anti-citrullinated protein antibodies and the relevance of anti-CCP antibodies in daily clinical practice are reviewed.
No takes yet. Share an insight, caveat, or question.
López‐Longo et al. (2009) conducted a cohort in Rheumatoid arthritis (n=937). Anti-cyclic citrullinated peptide (anti-CCP) antibodies vs. Absence of anti-CCP antibodies was evaluated on Development of ischemic heart disease and other clinical correlates. The presence of anti-CCP antibodies in patients with rheumatoid arthritis was independently associated with the development of ischemic heart disease, worse joint involvement, and higher mortality.
Synapse has enriched 10 related papers. Consider them for comparative context: